| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |


From the Departments of Surgery,*
Pathology,
and Medical Research and
Education,
Veterans General HospitalTaipei
and School of Medicine, National Yang-Ming University; and the
Institute of Biomedical Sciences,§
Academia
Sinica, Taipei, Taiwan, Republic of China
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
MAPKs are activated by dual phosphorylation on the threonine and tyrosine residues by mitogen-activated protein kinase kinase . MAPKs are involved in the transduction of extracellular signals for growth factors or environmental stresses, which commonly result in cell growth or differentiation.8 The MAPK isoforms are distinguished into three subgroups based on the tripeptide dual phosphorylation motif: extracellular signal-regulated protein kinase (erk), c-Jun amino-terminal kinase (JNK), and p38/HOG kinase. Although erk1 and erk2 are involved in growth-factor signaling mechanisms, JNK and p38/HOG play essential roles in proinflammatory cytokines, UV radiation, and stress-related signal pathways.9 MKK4 is not only the main activator of JNK, but it can also phosphorylate p38.7 This cross-talk between two MAPK pathways places MKK4 in a central regulatory position in the cell stress response pathway.7,9 Therefore, MKK4 is also known as SEK1 (SAPK/ERK kinase-1) and JNK kinase. The potential role of MKK4 in tumor progression has attracted the attention of researchers because MAPKs affect cell proliferation, differentiation, and apoptosis. Homologous deletion and mutation of the MKK4 gene have been found in some human cancer tissues and cell lines.10,11 Thus far, there is no report of MKK4's potential clinical relevance in human gastric cancers.
Gastric cancer is the second most-common cancer type in the world and the fourth leading cause of cancer death in Taiwan. Gastric cancer also has a high incidence rate around the Far East region, including Japan, India, and Korea.12 The survival rate for gastric cancer is poor and research efforts need to focus on prognostic and diagnostic advances. Among the limited prognosis factors, two important factors that influence survival in resectable gastric cancer are the depth of invasion through the gastric wall and the presence or absence of regional lymph node involvement.13 In previous studies, we examined the expression profile of PTKs in a human gastric cancer cell line and one gastric cancer tissue.14,15 To gain further understanding of PTK expression profiles in human gastric cancers, in the present study we extended the profile analysis using matching normal gastric mucosa tissues from the same patients with degenerated primers from the highly conserved kinase domains using a reverse transcriptase-polymerase chain reaction approach. Because there are several hundred protein kinases that have been identified/cloned,3 it was important to use such an expression profiling technique in examining overall kinase expressions in the present study. We identified 50 different protein kinase genes expressed in human gastric cancer tissues and adjacent normal gastric mucosa tissues.
| Materials and Methods |
|---|
|
|
|---|
Gastric cancer tissues and their corresponding normal gastric mucosa tissues were obtained from patients who underwent gastrectomy at Veterans General HospitalTaipei. Informed consent was obtained from all patients. Specimens were immediately frozen in liquid nitrogen after resection. Total RNA was extracted from gastric cancer and normal mucosa tissues by direct guanidine isothiocyanate lysis and cesium-chloride gradient separation method as described.14 Reverse transcription was done with 2 µg of total RNA, oligo (dT)15, and Moloney murine leukemia virus (MMLV) reverse transcriptase from Promega (Madison, WI). Degenerated polymerase chain reaction (PCR) primers were derived from the conserved DFG and DVW motifs of the tyrosine-kinase catalytic domain. Three forward primers were designed from two amino acid sequences: 5'-K[V/I][S/C/G]DFG and 5'-K[V/I][A/S/T]DFG. One reverse primer was designed from the amino acid sequence of 5'-DVW[S/A][F/Y]G.14,15 The PCR reactions were conducted at a 42°C annealing temperature for five cycles and then at 55°C for 25 cycles. The final PCR products were eluted from gels and purified. After ligation with T-vector plasmid from Promega, the resulting recombinants were analyzed by performing sequence identifications on individual clones. Sequence comparison to the GenBank nonredundant database was performed using the BLAST server at the National Center for Biotechnology and Information, National Institutes of Health, Bethesda, MD. We analyzed 50 to 150 clones for each tissue sample. More than 95% of clones analyzed were protein kinases.
Immunohistochemical Staining of MKK4 Kinase
Human gastric adenocarcinoma tissues were obtained from 96
patients who underwent gastrectomy at the Department of Surgery,
Veterans General HospitalTaipei. Informed consent was obtained from
all patients. The pathological features of patients studied are listed
in Table 1
. None of the patients had
undergone chemotherapy or radiotherapy before surgery. The maximum time
between stomach removal and quenching of tissue was 1 hour. Tissue
blocks were fixed overnight at 4°C with 4% neutral-buffered
paraformaldehyde solution, dehydrated, cleared with Hemo-De solution
(Fisher, Pittsburgh, PA; ingredients: d-limonene, butylated
hydroxanisole), then embedded in wax. Five-µm thick sections were
used for staining. Gastric adenocarcinomas were histologically divided
into intestinal and diffuse by Laurens16
criteria, and
they existed either alone or in combination. MKK4 in gastric cancer
tissues was localized using the avidin-biotin-peroxidase complex
technique as described.17
Antibodies and blocking peptides
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). All other
histochemistry reagents were obtained from Vector Laboratories
(Burlingame, CA).
|
Assessment of MKK4 Immunoreactivity
All staining procedures were standardized and controlled with an autoimmunostaining workstation machine (Leica ST5050; Leica, Deerfield, IL). Stained tissue sections were independently viewed and recorded by two researchers, and reconfirmed if there was a discrepancy on the reading of a particular slide. For assessing MKK4 immunoreactivity, we used the ratio of positively stained epithelial cells to total epithelial cells. A minus symbol (-) was given if there were no positively stained cells. One plus sign (+) indicated that >1% but <25% of cells were positively stained. Two plus signs (++) indicated that there were 25 to 75% of cells stained for MKK4 immunoreactivity. Three plus signs (+++) were used if >75% of cells were positively stained. We did not consider the use of color intensity of immunohistochemical reactions in stained cells as an evaluating parameter because it is difficult to provide objective and quantitative measurement of color intensity. However, only weakly stained cells were observed occasionally in the matching normal (adjacent nontumor tissue) gastric epithelium.
Statistical Analysis
All data are expressed as means ± SD, and the correlation between various disease parameters were analyzed by Students t-test and chi-square test. The relapse-free survival and overall survival curves were generated using the Kaplan-Meier method. Significance of survival differences analyses using Coxs proportional hazard regression model were carried out to assess the independent contribution of each variable to relapse-free and overall survival. The difference was considered to be significant when the P value was less than 0.05.
| Results |
|---|
|
|
|---|
Because in vivo growth conditions and cellular
microenvironments are quite different from in vitro
conditions, we studied surgical tumor specimens rather than cultured
cells to gain insights into the clinical relevance of tyrosine kinase
expression. The in vitro cultured cells were maintained in
fetal bovine serum and supported on a two-dimensional plastic surface,
which may alter the gene expression pattern, including tyrosine
kinase.18
In the present study, we expanded previous
kinase profiles of cancer tissues by including matching normal gastric
mucosa to obtain a better overview of kinase expression in human
gastric cancer progression. As shown in Figure 1
, 150 to 170 bp of PCR products were
generated using a combination of three forward primers and one reverse
primer (indicated by the arrowheads). All reactions gave rise to
significant amounts of PCR products, with the F3/R1 pair producing the
highest yield. Similar results have been observed with RNA isolated
from other tissues and cell lines.14
This result reflected
differential codon usages of the three degenerated forward primers. In
previous studies, we had analyzed 110 clones from a gastric cancer
tissue,15
and here we further selected 50 clones from the
cancers matching normal gastric mucosa tissue. For an additional pair
of gastric cancers in the present study, 160 clones were analyzed for
gastric cancer tissue and 98 clones were analyzed for matching normal
mucosa tissue, respectively. More than 95% of clones analyzed
originated from protein kinase genes, thereby demonstrating the
specificity of the PCR primers used and the effectiveness of the PTK
profiling approach used in the present study.
|
Because of the limited numbers of clones analyzed (from 50 to 160 clones), it was not feasible to perform further statistical measurements of our profile results. Nonetheless, the number of varieties of PTKs identified in both PTK profiles of the normal tissues is the same. In total, 23 protein kinases were identified in both the normal gastric tissue from patient 1 (with 50 clones sequenced) and the normal tissue from patient 2 (with 98 clones sequenced). We found that 11 kinases overlapped in both normal tissue PTK profiles and that they represented almost all of the abundantly expressed PTKs, with the exception of jak1 and cak in patient 2. Because of the heterogeneous nature of clinical samples, it is intriguing that the representation of PTKs was somewhat compatible in both normal gastric mucosa tissues. This implied that our PTK profiles could still provide a common expression pattern, even with limited numbers of clones analyzed.
However, it was difficult to make similar observations in gastric cancer tissues because of the aberrant gene expression patterns and possible amplification of some PTKs. Nevertheless, a variety of PTKs have been identified in gastric cancer tissues and many of them were not previously implicated in gastric cancers. This PTK profile information provided us an excellent opportunity to be able to choose several important protein kinase genes, which may play critical functions in human gastric cancer progression, out of hundreds of kinases. Subsequent immunohistochemical analysis with archived tissue sections can then be performed with specific PTK antibodies. This approach allowed us to examine large number of samples, to confirm the PTK expression on which particular cell types, and to perform retrospective statistical analysis with clinicopathological features.
To further assist our identification of important PTKs in human gastric
cancer progression, we established and analyzed PTK profiles from two
sets of different gastric cancer tissues with matching pairs of normal
tissues. The expression of the PTK genes identified is summarized in
Figure 2
. In the first pair of tissues
(Figure 2
, top panel), a total of 32 different PTK genes were
identified, including receptor-type PTK genes (14 genes),
nonreceptor-type PTK genes (10 genes), as well as dual and other
kinases (7 genes). One possible new protein kinase gene was identified.
In the second pair of tissues (Figure 2
, bottom panel), a total of 34
different PTK genes were identified, including receptor-type PTK genes
(12 genes), nonreceptor-type PTK genes (10 genes), as well as dual and
other kinases (6 genes). Six possible new protein kinase genes were
identified. In total, we observed 50 different protein kinases in human
gastric tissues and cancers. Differential expression patterns of PTKs
in normal and cancer tissues were noted. For example, the
tie-1 gene was significantly over-expressed in cancer
tissues in patient 1 (Figure 2)
. There were seven nonreceptor-type
PTKs, seven receptor-type PTKs, one dual kinase, and one novel kinase
presented in both profiles. Among these PTKs, several genes such as
fyn, itk, tyk2 (nonreceptor PTK);
c-fms, c-kit, cak, tie-1
(receptor PTK); MKK4 (dual kinase) seemed to be expressed
more frequently in cancer tissues than in normal tissues. Several of
these tyrosine kinases are potentially related to hematopoietic cells,
such as fyn, itk, c-fms, and
c-kit. It is likely that infiltrating lymphocytes are
responsible for expression of these protein tyrosine kinases, not
gastric cancer cells. Among the remaining PTKs, we previously examined
the expression of tie-1 protein in human gastric cancer tissue sections
and found that tie-1 can serve as an independent prognostic
biomarker.15
Therefore, in the present study we examined
the expression of the MKK4 gene in gastric cancer tissues by
immunohistochemistry to better determine MKK4s clinical
relevance in gastric cancers.
|
As illustrated in Figure 3A
,
immunoreactivity of MKK4 in gastric cancer tissue revealed fine
reddish-brown particles. Positive MKK4 kinase immunoreactivity existed
in the cytoplasm and nucleus. This immunoreactivity was totally blocked
by specific MKK4 blocking peptide (Figure 3B)
, attesting to the
specificity of the antibody. MKK4 proteins were observed in 44.8% (43
out of 96) of gastric adenocarcinomas and were heterogeneous in type;
the intensity varied from weak to strong in different cells in the same
cancer cell nests. No MKK4 protein immunoreactivity was observed in
muscular and serosal tissues.
|
The color intensity of immunohistochemical reaction products was also much higher in tumor cells compared with the intensity in normal epithelium, implying a higher expression level of MKK4 in gastric cancer cells. Because of the lack of objective and quantitative measurement means, we did not use this parameter in our analysis. MKK4 expression in tumor tissues actually affected tumor behavior, and its effects on survival were identical to the aforementioned data (normal versus tumor MKK4 immunoreactivity). Therefore, we decided to evaluate the clinicopathological relevance of MKK4 expression in tumor tissue sections. Relations between MKK4 status in gastric cancer tissues and other clinicopathological parameters were determined. There was no significant association between MKK4 status and age (P = 0.70), sex (P = 0.40), tumor size (P = 0.80), tumor location (P = 0.74), gross tumor type (P = 0.27), stromal reaction pattern (P = 0.63), depth of cancer invasion (P = 0.84), lymphatic invasion (P = 0.75), vessel invasions (P = 0.75), lymph node metastasis (P = 0.05), liver metastasis (P = 0.73), peritoneal dissemination (P = 0.46), Laurens histological classification (P = 0.37), or TNM stage (P = 0.12). Several investigators previously suggested that tyrosine kinases, such as the c-met receptor PTK, might participate in the formation of lumen-like structures in human mammary ducts, epithelial carcinoma cell lines,19 and stomach cancer.20 However, in the present study we did not observe a relationship between MKK4 protein expression and intestinal type gastric cancer (P = 0.366). Moreover, postrecurrence treatments such as chemotherapy or regional radiotherapy did not alter MKK4 biological behavior (data not shown).
Figure 4
shows relapse-free and overall
survival curves according to MKK4 status. These curves visually
represent the increased hazard rates of study subjects who showed MKK4
expression in their gastric cancer tissues. In univariate analysis
concerning relapse-free and overall survival rate in gastric cancer
patients, significant prognostic factors were tumor size
(P < 0.001, P = 0.001), stromal
reaction pattern (P = 0.031, P =
0.010), depth of cancer invasion (P = 0.002,
P < 0.001), lymph node metastasis
(P = 0.002, P < 0.001), liver
metastases (P = 0.007, P <
0.001), peritoneal dissemination (P < 0.001,
P < 0.001), TNM stage (P <
0.001, P < 0.001), and MKK4 immunoreactivity
(P = 0.008, P = 0.004).
Lymphatic duct invasion (P = 0.017) and vessel
invasion (P = 0.013) were two significant
factors affecting overall survival, but not relapse-free survival. Age,
gender, location of tumor, and gross tumor appearance were not
prognostic factors affecting relapse-free survival or overall survival.
After the univariate study, multivariate analysis was conducted to test
the independent prognostic role of these variables. When all
significant variables were taken into account through a stepwise
analysis, the model selected MKK4 expression as the single
independent factor regarding relapse-free survival
(P = 0.002; hazard ratio = 2.1).
Tumor size came next (P < 0.001, hazard
ratio = 2.0), then TNM stage (P < 0.001,
hazard ratio = 1.9) (Table 2)
.
Regarding overall survival, the model selected TNM stage as the most
powerful independent factor (P < 0.001, hazard
ratio = 3.1). MKK4 status came next (P =
0.007, hazard ratio = 2.1). Stromal reaction pattern, depth of
cancer invasion, lymph node metastasis, liver metastases, peritoneal
dissemination, lymphatic duct invasion, and vessel invasion were not
significant prognostic factors (Table 2)
.
|
|
|
| Discussion |
|---|
|
|
|---|
One particular PTK, c-erbB2/neu, has been implicated in gastric cancer progression.5 Amplification of c-erbB2/neu was observed in ~18% to 24% of differentiated gastric cancers.25 Although we did identify c-erbB2/neu or another oncogenic receptor PTK, c-met, in our profiles, they were not over-expressed in tumor tissues analyzed here. This may be attributed to individual patient variations, as a similar PTK profiling procedure readily identified the expression of c-erbB2/neu in prostate cancer tissues.23
Evidence indicates that lymph node metastasis, depth of cancer invasion, gross appearance of the tumor,26,27 and stromal reaction27 are independent factors that affect survival in patients with gastric cancer. The present study showed that MKK4 kinase expression was not associated with these factors. Furthermore, our statistical analyses showed that MKK4 protein expression in primary gastric adenocarcinoma tissue is a useful prognostic marker for identifying high- and low-risk patients. Gastric adenocarcinoma patients with MKK4 present in gastric cancer tissue had a significantly shorter relapse-free survival and overall shorter survival compared to patients without MKK4 expression. In multivariate analysis, MKK4 was found to be an independent and powerful prognostic factor (relative risk = 2.1) in gastric cancer. Because the relative impact of prognostic factors on relapse-free survival and overall survival reflects these prognostic factors respective roles in tumor biology, we speculate that MKK4 may play an important role in the progression of human gastric cancer.
MKK4 plays particularly important roles in embryonic development. MKK4 knock-out mice are embryonic lethal; MKK4 (-/-) cells are defective in the downstream JNK and AP-1 activities, indicating the essential roles of MKK4 in the JNK signaling pathway.28 The most intriguing observation from these knock-out mice was the abnormal hepatogenesis and massive hepatocyte apoptosis that indicate the MKK4-JNK pathway plays an essential role in liver development.29 These data strongly suggest that MKK4-JNK is essential in protecting hepatocytes from apoptosis in embryonic development; however, contradicting evidence indicates that MKK4 involvement in the apoptosis mechanism is mediated by different stimuli.30 The MKK4-JNK pathway is a complicated signaling network, and further research needs to be conducted using various cell types and distinct stimuli. JNK and p38 pathways were up-regulated, including MKK4, when cells were exposed to alkylating agents like methyl methanesulfonate.31 These data indicate that MKK4 could be part of a defense mechanism for cell damaging reagents in cancer cells. It will be important to examine MKK4 kinase activity in tissue sections to understand the activation status of MKK4-JNK pathway. This can be achieved by applying suitable phospho-specific antibodies.
It was previously demonstrated that some human cancer tissues and cell lines have MKK4 genetic changes and lose MKK4 protein expressions or activities. Homozygous deletions were detected in two of 92 pancreatic adenocarcinomas (2%), one of 16 biliary adenocarcinomas (6%), and three of 22 breast carcinomas (15%), and one somatic mis-sense mutation of MKK4 was observed in 45 pancreatic carcinomas.10 Teng et al11 reported homozygous deletions in cancer cell lines originating from pancreas and lung cancer lines and four cancer cell lines harboring mutations lost MKK4 kinase activity (in total, six out of 213 cell lines, ~3%). A major difference between these studies and our report is that in the previous studies a pure cancer cell population was required for DNA preparation and loss of heterozygosity analysis. Therefore, in the previous studies cell lines or xenograft tumor samples were prepared. As mentioned earlier, PTK expression pattern can be altered under different growth environments. In addition, the previous studies did not examine the correlation between the expression of MKK4 protein and clinicopathological features of tumors.
It is possible that multiple genetic alterations are involved in the process of oncogenesis of gastric cancers, and MKK4 might be involved in various signaling pathways. As discussed above, MKK4 is involved in several complicated signaling networks and might play different biological functions in different pathways. We found that only 44.8% of gastric adenocarcinomas examined expressed MKK4 protein, suggesting that genetic alterations of the MKK4 gene may exist in gastric cancer tissues. Loss of MKK4 immunoreactivity in cancer tissues was observed in 46 cases (48% of total samples), while their matching normal tissues were positive for MKK4 expression. Some of these tumors might lose the MKK4 gene loci or otherwise mutate as previously reported,10,11 hence the exact roles of MKK4 need to be further elucidated. However, there is a previous example of a tumor suppressor gene over-expressed in the late stage of tumors. p53 is a well-known tumor suppressor gene in human cancers including gastric cancers.25 Mutation of the p53 gene (without loss of heterozygosity phenotype) generated mutant p53 protein with an extended half-life, which resulted in an immunoreactivity against p53 protein. We observed the MKK4 transcript in several gastric cancer tissues examined by reverse transcriptase-polymerase chain reaction (data not shown). Because of the mixtures of cell types in the resected gastric cancer tissues, we were not able to confirm the genetic alterations of the MKK4 gene specifically in cancer cells. Further experiments are required to examine the MKK4 gene transcript in cancer cells only using laser-captured microdissection instruments.
In summary, in the present study we developed a general tyrosine kinase profile for gastric cancer specimens and their normal tissue counterparts, and then examined the in situ expression pattern of a particular PTK (MKK4) identified from the profile by immunohistochemistry. We conclude that MKK4 expression is an independent and powerful prognostic factor in human gastric cancers.
| Acknowledgements |
|---|
| Footnotes |
|---|
Supported by grants from the National Science Council (NSC 89-2314-B-075-077-M58, and NSC 89-2314-B-001-010-M58).
Accepted for publication February 16, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M.-Y. Son, J. Kim, H.-W. Han, S.-M. Woo, Y. S. Cho, Y.-K. Kang, and Y.-M. Han Expression profiles of protein tyrosine kinase genes in human embryonic stem cells Reproduction, October 1, 2008; 136(4): 423 - 432. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Y. Wang, M. Iordanov, and Q. Zhang c-Jun NH2-terminal Kinase Promotes Apoptosis by Down-regulating the Transcriptional Co-repressor CtBP J. Biol. Chem., November 17, 2006; 281(46): 34810 - 34815. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Cunningham, F. Kamangar, M. P. Kim, S. Hammoud, R. Haque, C. Iacobuzio-Donahue, R. Ashfaq, S. E. Kern, A. Maitra, R. E. Heitmiller, et al. MKK4 Status Predicts Survival After Resection of Gastric Adenocarcinoma Arch Surg, November 1, 2006; 141(11): 1095 - 1099. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Kennedy, H. K. Sluss, S. N. Jones, D. Bar-Sagi, R. A. Flavell, and R. J. Davis Suppression of Ras-stimulated transformation by the JNK signal transduction pathway Genes & Dev., March 1, 2003; 17(5): 629 - 637. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Kim, D. J. Vander Griend, X. Yang, D. A. Benson, Z. Dubauskas, B. A. Yoshida, M. A. Chekmareva, Y. Ichikawa, M. H. Sokoloff, P. Zhan, et al. Mitogen-activated Protein Kinase Kinase 4 Metastasis Suppressor Gene Expression Is Inversely Related to Histological Pattern in Advancing Human Prostatic Cancers Cancer Res., April 1, 2001; 61(7): 2833 - 2837. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |